{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:15:05Z","timestamp":1788279305320,"version":"build-2803163510"},"reference-count":117,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA 233610-2"],"award-info":[{"award-number":["R01CA 233610-2"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 HL150069"],"award-info":[{"award-number":["R01 HL150069"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lymphoma &amp; Leukemia Society","award":["Scholar Award"],"award-info":[{"award-number":["Scholar Award"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Certain cancer treatments have been linked to specific cardiovascular toxicities, including (but not limited to) cardiomyopathy, atrial fibrillation, arterial hypertension, and myocarditis. Radiation, anthracyclines, human epidermal growth factor receptor 2 (Her2)-directed therapies, fluoropyrimidines, platinums, tyrosine kinase inhibitors and proteasome inhibitors, immune checkpoint inhibitors, and chimeric antigen-presenting (CAR)-T cell therapy can all cause cardiovascular side effects. Management of cardiovascular dysfunction that occurs during cancer therapy often requires temporary or permanent cessation of the risk-potentiating anti-neoplastic drug as well as optimization of medical management from a cardiovascular standpoint. Stem cell or bone marrow transplant recipients face unique cardiovascular challenges, as do patients at extremes of age.<\/jats:p>","DOI":"10.3390\/cancers12123737","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:45:36Z","timestamp":1607906736000},"page":"3737","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cardiovascular Health during and after Cancer Therapy"],"prefix":"10.3390","volume":"12","author":[{"given":"Kathryn J.","family":"Ruddy","sequence":"first","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra S.","family":"Higgins","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2604-8603","authenticated-orcid":false,"given":"Saro H.","family":"Armenian","sequence":"additional","affiliation":[{"name":"Department of Population Sciences, City of Hope, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circ. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Roychoudhuri, R., Robinson, D., Putcha, V., Cuzick, J., Darby, S., and Moller, H. (2007). Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: A population-based study. BMC Cancer, 7.","DOI":"10.1186\/1471-2407-7-9"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"Schaapveld","year":"2015","journal-title":"JAMA Intern Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1002\/hsr2.135","article-title":"Treatment for lymphoma and late cardiovascular disease risk: A systematic review and meta-analysis","volume":"2","author":"Stone","year":"2019","journal-title":"Health Sci. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.amjcard.2019.07.015","article-title":"Percutaneous Coronary Intervention and Outcomes in Patients With Lymphoma in the United States (Nationwide Inpatient Sample [NIS] Analysis)","volume":"124","author":"Borovac","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","article-title":"Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: Pathophysiology, course, monitoring, management, prevention, and research directions: A scientific statement from the American Heart Association","volume":"128","author":"Lipshultz","year":"2013","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/4130824","article-title":"Amifostine Pretreatment Attenuates Myocardial Ischemia\/Reperfusion Injury by Inhibiting Apoptosis and Oxidative Stress","volume":"2017","author":"Wu","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: An update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment","volume":"7","author":"Volkova","year":"2012","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0002-9343(78)90802-1","article-title":"Early anthracycline cardiotoxicity","volume":"65","author":"Bristow","year":"1978","journal-title":"Am. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","article-title":"Underlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy","volume":"342","author":"Felker","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.1049","article-title":"Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: A single centre experience","volume":"20","author":"Fornaro","year":"2017","journal-title":"Eur. J. Hear. Fail."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacep.2016.08.009","article-title":"Burden of Cardiac Arrhythmias in Patients With Anthracycline-Related Cardiomyopathy","volume":"3","author":"Mazur","year":"2017","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ccl.2019.07.009","article-title":"Cardiomyopathy Prevention in Cancer Patients","volume":"37","author":"Barbar","year":"2019","journal-title":"Cardiol. Clin."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/456409","article-title":"Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review","volume":"2013","author":"Lao","year":"2013","journal-title":"J. Drug Deliv."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Xing, M., Yan, F., Yu, S., and Shen, P. (2015). Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133569"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e015327","DOI":"10.1161\/JAHA.119.015327","article-title":"The Role of Angiotensin-Converting Enzyme Inhibitors and beta-Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients","volume":"9","author":"Brown","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of High-Dose Chemotherapy\u2013Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1054\/ejon.2000.0072","article-title":"What is HER2?","volume":"4","author":"Cooke","year":"2000","journal-title":"Eur. J. Oncol. Nurs."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Hurwitz","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1111\/bph.13643","article-title":"Trastuzumab cardiotoxicity: From clinical trials to experimental studies","volume":"174","author":"Nemeth","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1200\/JCO.2015.64.5515","article-title":"Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter","volume":"34","author":"Dang","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e008637","DOI":"10.1161\/JAHA.118.008637","article-title":"Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction","volume":"7","author":"Nowsheen","year":"2018","journal-title":"J. Am. Hear. Assoc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: The SAFE-HEaRt study","volume":"175","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","article-title":"Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity","volume":"1","author":"Leong","year":"2019","journal-title":"JACC CardioOncology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101\u2013Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_33","first-page":"392","article-title":"Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity","volume":"18","author":"Charbonnel","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","article-title":"Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2019.11.023","article-title":"Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer","volume":"126","author":"Ameye","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1634\/theoncologist.2012-0448","article-title":"Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study","volume":"18","author":"Swain","year":"2013","journal-title":"Oncologist"},{"key":"ref_37","unstructured":"(2020, November 15). AstraZeneca, ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) for Injection, for Intravenous Use: HIGHLIGHTS OF PRESCRIBING INFORMATION. Initial U.S. Approval: 2019, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761139s000lbl.pdf."},{"key":"ref_38","unstructured":"Seagen Inc (2020, November 15). Highlights of Prescribing Information These Highlights Do Not Include All the Information Needed to use TUKYSA Safely and Effectively. See Full Prescribing Information for TUKYSA, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213411s000lbl.pdf."},{"key":"ref_39","unstructured":"(2020, November 15). GlaxoSmithKline, TYKERB (lapatinib) Tablets; HIGHLIGHTS OF PRESCRIBING INFORMATION. Initial U.S. Approval: 2007, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022059s3s6lbl.pdf."},{"key":"ref_40","unstructured":"Genetech Inc. (2020, November 15). KADCYLA\u00ae (ado-trastuzumab emtansine) for Injection, for Intravenous Use: HIGHLIGHTS OF PRESCRIBING INFORMATION. Initial U.S. Approval: 2013, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125427s105lbl.pdf."},{"key":"ref_41","unstructured":"Genetech, I. (2020, November 15). PERJETATM (pertuzumab) Injection, for Intravenous Use: HIGHLIGHTS OF PRESCRIBING INFORMATION. Initial U.S. Approval: 2012, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125409lbl.pdf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1002\/ijc.28234","article-title":"Cardiac toxicity in breast cancer patients treated with dual HER2 blockade","volume":"133","author":"Valachis","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1752-1947-8-252","article-title":"Cardiotoxicity following cyclophosphamidetherapy: A case report","volume":"8","author":"Atalay","year":"2014","journal-title":"J. Med. Case Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/106002809402800314","article-title":"Fluorouracil Cardiotoxicity","volume":"28","author":"Anand","year":"1994","journal-title":"Ann. Pharmacother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3747\/co.v17i1.437","article-title":"Capecitabine-induced cardiotoxicity: Case report and review of the literature","volume":"17","author":"Ang","year":"2010","journal-title":"Curr. Oncol."},{"key":"ref_47","unstructured":"Kanduri, J., and Asnani, A. (2020, December 01). Fluoropyrimidine Cardiotoxicity. American College of Cardiology. Available online: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2019\/04\/05\/07\/34\/fluoropyrimidine-cardiotoxicity."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-019-0048-3","article-title":"5-FU induced cardiotoxicity: Case series and review of the literature","volume":"5","author":"Yuan","year":"2019","journal-title":"Cardio-Oncology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1758835918780140","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: A review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/annonc\/mdf108","article-title":"Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil","volume":"13","author":"Hoff","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: Revisited","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.clcc.2018.09.006","article-title":"Bolus 5-fluorouracil (5-FU) In Combination with Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine","volume":"18","author":"Chakrabarti","year":"2019","journal-title":"Clin. Color. Cancer"},{"key":"ref_53","first-page":"369","article-title":"Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer","volume":"5","author":"Cimino","year":"2013","journal-title":"Bioanalytical"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"537","DOI":"10.6004\/jnccn.2012.0051","article-title":"Late Cardiovascular Toxicity Following Chemotherapy for Germ Cell Tumors","volume":"10","author":"Feldman","year":"2012","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6904-8-7","article-title":"Long-term platinum retention after treatment with cisplatin and oxaliplatin","volume":"8","author":"Brouwers","year":"2008","journal-title":"BMC Clin. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular Risk Factors and Morbidity in Long-Term Survivors of Testicular Cancer: A 20-Year Follow-Up Study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/ijc.33119","article-title":"Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors","volume":"147","author":"Lin","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular toxic effects of cancer therapies","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_60","first-page":"1","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","article-title":"Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials","volume":"2","author":"Chari","year":"2018","journal-title":"Blood Adv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in UntreatedEGFR-Mutated Advanced Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_63","unstructured":"Network N.C.C. (2020, August 12). NCCN Guidelines. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2020.02.003","article-title":"Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib","volume":"2","author":"Kunimasa","year":"2020","journal-title":"JACC CardioOncol."},{"key":"ref_65","first-page":"651","article-title":"Osimertinib-induced Cardiomyopathy: Case series and review of the literature","volume":"2","author":"Patel","year":"2019","journal-title":"JACC Case Rep."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Archibald, W.J., Rabe, K.G., Kabat, B.F., Herrmann, J., Ding, W., Kay, N.E., Kenderian, S.S., Muchtar, E., Leis, J.F., and Wang, Y. (2020). Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: Risk prediction, management, and clinical outcomes. Ann. Hematol.","DOI":"10.1007\/s00277-020-04094-3"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-Associated Atrial Fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000498985","article-title":"Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature","volume":"12","author":"Agrawal","year":"2019","journal-title":"Case Rep. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41379-019-0363-0","article-title":"Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms","volume":"33","author":"Champion","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J. Am. Hear. Assoc."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T Cell Therapy\u2013Related Cardiovascular Outcomes and Management","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMra1712502","article-title":"Cancer Survivorship","volume":"379","author":"Shapiro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3322\/caac.21565","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA A Cancer J. Clin."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1158\/1055-9965.EPI-06-0714","article-title":"Health Care Utilization by Adult Long-term Survivors of Hematopoietic Cell Transplant: Report from the Bone Marrow Transplant Survivor Study","volume":"16","author":"Shankar","year":"2007","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2005-01-0035","article-title":"Late mortality in survivors of autologous hematopoietic-cell transplantation: Report from the Bone Marrow Transplant Survivor Study","volume":"105","author":"Bhatia","year":"2005","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-155-1-201107050-00004","article-title":"Cardiovascular Hospitalizations and Mortality among Recipients of Hematopoietic Stem Cell Transplantation","volume":"155","author":"Chow","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bbmt.2016.08.019","article-title":"National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report","volume":"23","author":"Armenian","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cncr.28444","article-title":"Cardiovascular disease in survivors of hematopoietic cell transplantation","volume":"120","author":"Armenian","year":"2014","journal-title":"Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1182\/blood-2012-06-437178","article-title":"Cardiovascular risk factors in hematopoietic cell transplantation survivors: Role in development of subsequent cardiovascular disease","volume":"120","author":"Armenian","year":"2012","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1200\/JCO.2008.17.7428","article-title":"Late congestive heart failure after hematopoietic cell transplantation","volume":"26","author":"Armenian","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/bloodadvances.2018019117","article-title":"Prediction of cardiovascular disease among hematopoietic cell transplantation survivors","volume":"2","author":"Armenian","year":"2018","journal-title":"Blood Adv."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2013.52.6582","article-title":"Influence of Conventional Cardiovascular Risk Factors and Lifestyle Characteristics on Cardiovascular Disease After Hematopoietic Cell Transplantation","volume":"32","author":"Chow","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Arranto, C.A., Burkard, T., Leuppi-Taegtmeyer, A.B., Gerull, S., Passweg, J.R., Pfister, O., and Halter, J. (2020). Prevalence of untreated and uncontrolled cardiovascular risk factors in survivors of allogeneic cell transplantation. Bone Marrow Transplant., 1\u20138.","DOI":"10.1038\/s41409-020-00997-x"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1161\/CIRCULATIONAHA.114.008820","article-title":"ABCDE Steps to Prevent Heart Disease in Breast Cancer Survivors","volume":"130","author":"Montazeri","year":"2014","journal-title":"Circulation"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_93","unstructured":"American College of Cardiology (2020, December 10). ASCVD Risk Estimator Plus. Available online: http:\/\/tools.acc.org\/ascvd-risk-estimator-plus\/#!\/calculate\/estimate\/."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1161\/CIRCULATIONAHA.119.044282","article-title":"Secondary Prevention for Atherosclerotic Cardiovascular Disease: Comparing Recent US and European Guidelines on Dyslipidemia","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","article-title":"Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association","volume":"139","author":"Gilchrist","year":"2019","journal-title":"Circulation"},{"key":"ref_96","first-page":"1","article-title":"Sex-Related Differences in Dilated Cardiomyopathy with a Focus on Cardiac Dysfunction in Oncology","volume":"22","author":"Camilli","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"784","DOI":"10.6004\/jnccn.2019.0034","article-title":"NCCN Guidelines Insights: Survivorship, Version 2.2019","volume":"17","author":"Sanft","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e005984","DOI":"10.1161\/CIRCOUTCOMES.119.005984","article-title":"Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy","volume":"13","author":"Ruddy","year":"2020","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/asheducation-2018.1.146","article-title":"Long-term complications in adolescent and young adult leukemia survivors","volume":"2018","author":"Baker","year":"2018","journal-title":"Hematology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/jama.1993.03510160067031","article-title":"Factors affecting late mortality from heart disease after treatment of Hodgkin\u2019s disease","volume":"270","author":"Hancock","year":"1993","journal-title":"JAMA"},{"key":"ref_103","first-page":"33","article-title":"Long-term survival in Hodgkin\u2019s disease relative impact of mortality, second tumors, infection, and cardiovascular disease","volume":"1","author":"Mauch","year":"1995","journal-title":"Cancer J. Sci. Am."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2006","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2015.65.5845","article-title":"Cardiovascular Disease Risk Profiles in Survivors of Adolescent and Young Adult (AYA) Cancer: The Kaiser Permanente AYA Cancer Survivors Study","volume":"34","author":"Chao","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jgo.2015.12.002","article-title":"Comorbidity in older adults with cancer","volume":"7","author":"Williams","year":"2016","journal-title":"J. Geriatr. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/CLEP.S47150","article-title":"The impact of comorbidity on cancer survival: A review","volume":"5","author":"Sogaard","year":"2013","journal-title":"Clin. Epidemiol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Fourcadier, E., Trouche-Sabatier, S., Gras-Aygon, C., Ecarnot, F., Daur\u00e8s, J.-P., and Bessaoud, F. (2015). Under-treatment of elderly patients with ovarian cancer: A population based study. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1947-9"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/annonc\/mdv018","article-title":"Approach to therapy of diffuse large B-cell lymphoma in the elderly: The International Society of Geriatric Oncology (SIOG) expert position commentary","volume":"26","author":"Morrison","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/heartjnl-2015-307894","article-title":"Roadmap for biomarkers of cancer therapy cardiotoxicity","volume":"102","author":"Yu","year":"2016","journal-title":"Heart"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jbi.2015.06.003","article-title":"Mobile-health: A review of current state in 2015","volume":"56","author":"Silva","year":"2015","journal-title":"J. Biomed. Inform."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.2196\/medinform.6603","article-title":"Adopting Telemedicine for the Self-Management of Hypertension: Systematic Review","volume":"5","author":"Mileski","year":"2017","journal-title":"JMIR Med. Inform."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3389\/fphar.2017.00330","article-title":"Telemedicine for the Management of Glycemic Control and Clinical Outcomes of Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Studies","volume":"8","author":"Lee","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_114","first-page":"34","article-title":"Telecardiology during the Covid-19 pandemic: Past mistakes and future hopes","volume":"10","author":"Guarise","year":"2020","journal-title":"Am J Cardiovasc Dis"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.6004\/jnccn.2018.7005","article-title":"Secondary Neoplasms of the Female Lower Genital Tract after Hematopoietic Cell Transplantation","volume":"16","author":"Chang","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3389\/fonc.2019.01505","article-title":"Exercise Promotion and Distress Reduction Using a Mobile App-Based Community in Breast Cancer Survivors","volume":"9","author":"Chung","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s11764-019-00777-7","article-title":"The use of mobile technology and peer navigation to promote adolescent and young adult (AYA) cancer survivorship care: Results of a randomized controlled trial","volume":"13","author":"Casillas","year":"2019","journal-title":"J. Cancer Surviv."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/12\/3737\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:44:08Z","timestamp":1760179448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/12\/3737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":117,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["cancers12123737"],"URL":"https:\/\/doi.org\/10.3390\/cancers12123737","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]}}}